A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.
Nykode Therapeutics AS (OTCMKTS:VACBF – Get Free Report) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 593,100 shares, a drop of 30.2% from the November 15th total of 849,200 shares. Based on an average daily trading volume, of 0 shares, the short-interest […]
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S , a.
Nykode Therapeutics - Quarterly report Q3 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Nykode Therapeutics - Quarterly Report Q3 2023 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.